个性化文献订阅>期刊> Bioorganic & Medicinal Chemistry Letters
 

Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain

  作者 Meyers, MJ; Long, SA; Pelc, MJ; Wang, JL; Bowen, SJ; Schweitzer, BA; Wilcox, MV; McDonald, J; Smith, SE; Foltin, S; Rumsey, J; Yang, YS; Walker, MC; Kamtekar, S; Beidler, D; Thorarensen, A  
  选自 期刊  Bioorganic & Medicinal Chemistry Letters;  卷期  2011年21-21;  页码  6545-6553  
  关联知识点  
 

[摘要]Fatty acid amide hydrolase (FAAH) is an integral membrane serine hydrolase responsible for the degradation of fatty acid amide signaling molecules such as endocannabinoid anandamide (AEA), which has been shown to possess cannabinoid-like analgesic properties. Herein we report the optimization of spirocyclic 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane urea covalent inhibitors of FAAH. Using an iterative design and optimization strategy, lead compounds were identified with a remarkable reduction in molecular weight and favorable CNS drug like properties. 3,4-Dimethylisoxazole and 1-methyltetrazole were identified as superior urea moieties for this inhibitor class. A dual purpose in vivo efficacy and pharmacokinetic screen was designed to be the key decision enabling experiment affording the ability to move quickly from compound synthesis to selection of preclinical candidates. On the basis of the remarkable potency, selectivity, pharmacokinetic properties and in vivo efficacy, PF-04862853 (15p) was advanced as a clinical candidate. (C) 2011 Elsevier Ltd. All rights reserved.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内